| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6949571 | CATALYST PHARMS | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
Jun, 2024
(a month from now) | |
| US8772497 | CATALYST PHARMS | Method for producing 1, 2-dihydropyridine-2-one compound |
Jul, 2026
(2 years from now) | |
Fycompa is owned by Catalyst Pharms.
Fycompa contains Perampanel.
Fycompa has a total of 2 drug patents out of which 0 drug patents have expired.
Fycompa was authorised for market use on 29 April, 2016.
Fycompa is available in suspension;oral, tablet;oral dosage forms.
Fycompa can be used as treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy.
Drug patent challenges can be filed against Fycompa from 22 October, 2016.
The generics of Fycompa are possible to be released after 01 July, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2017 |
Drugs and Companies using PERAMPANEL ingredient
NCE-1 date: 22 October, 2016
Market Authorisation Date: 29 April, 2016
Treatment: Treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy
Dosage: SUSPENSION;ORAL; TABLET;ORAL
FYCOMPA family patents
